Ra Pharmctl Inc (NASDAQ:RARX) – Analysts at Jefferies Group issued their Q1 2018 earnings estimates for shares of Ra Pharmctl in a report issued on Thursday. Jefferies Group analyst E. Yang expects that the company will post earnings per share of ($0.77) for the quarter. Jefferies Group currently has a “Buy” rating and a $25.00 target price on the stock. Jefferies Group also issued estimates for Ra Pharmctl’s Q2 2018 earnings at ($0.91) EPS, Q3 2018 earnings at ($0.93) EPS and Q4 2018 earnings at ($1.14) EPS.
Ra Pharmctl (NASDAQ:RARX) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.06). COPYRIGHT VIOLATION WARNING: This piece was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/11/14/q1-2018-earnings-estimate-for-ra-pharmctl-inc-issued-by-jefferies-group-rarx.html.
RARX has been the topic of several other reports. Zacks Investment Research raised Ra Pharmctl from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th. Royal Bank Of Canada started coverage on Ra Pharmctl in a report on Thursday, September 14th. They set an “outperform” rating and a $21.00 price target on the stock. Finally, Credit Suisse Group increased their price target on Ra Pharmctl from $19.00 to $23.00 and gave the company an “outperform” rating in a report on Friday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $24.67.
Ra Pharmctl (NASDAQ RARX) opened at $14.11 on Monday. Ra Pharmctl has a twelve month low of $11.20 and a twelve month high of $27.84.
A number of institutional investors have recently made changes to their positions in RARX. American International Group Inc. bought a new position in Ra Pharmctl in the 1st quarter worth $102,000. TIAA CREF Investment Management LLC raised its holdings in Ra Pharmctl by 97.0% in the 1st quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock worth $167,000 after purchasing an additional 3,859 shares during the period. Alliancebernstein L.P. bought a new position in Ra Pharmctl in the 2nd quarter worth $195,000. Wells Fargo & Company MN raised its holdings in Ra Pharmctl by 151.8% in the 1st quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock worth $202,000 after purchasing an additional 5,700 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in Ra Pharmctl by 30.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock worth $204,000 after purchasing an additional 2,543 shares during the period. 66.74% of the stock is currently owned by institutional investors.
About Ra Pharmctl
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.